varespladib has been researched along with varespladib methyl in 4 studies
| Studies (varespladib) | Trials (varespladib) | Recent Studies (post-2010) (varespladib) | Studies (varespladib methyl) | Trials (varespladib methyl) | Recent Studies (post-2010) (varespladib methyl) |
|---|---|---|---|---|---|
| 80 | 11 | 49 | 22 | 4 | 19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bickler, P; Lewin, M; Merkel, J; Samuel, S | 1 |
| Gutiérrez, JM; Lewin, MR; Lomonte, B; Williams, DJ | 1 |
| Fortes-Dias, CL; Garrido Cavalcante, WL; Gonçalves de Abreu, TA; Maciel, FV; Ortolani, PL; Ramos Pinto, ÊK; Valério Souza, NM | 1 |
| Akpunonu, PD; Bammigatti, C; Bhalla, A; Carter, RW; Gerardo, CJ; Kotehal, SD; Kumar, S; Lewin, MR; Manikath, N; Mukherjee, PP; Platts-Mills, TF; Samuel, SP; Shirazi, FM | 1 |
1 trial(s) available for varespladib and varespladib methyl
| Article | Year |
|---|---|
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming.
Topics: Clinical Trials, Phase II as Topic; Female; Humans; Male; Multicenter Studies as Topic; Phospholipases A2, Secretory; Randomized Controlled Trials as Topic; Snake Bites | 2022 |
3 other study(ies) available for varespladib and varespladib methyl
| Article | Year |
|---|---|
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.
Topics: Acetates; Animals; Antidotes; Disease Models, Animal; Dose-Response Relationship, Drug; Elapid Venoms; Indoles; Keto Acids; Mice; Phospholipase A2 Inhibitors; Phospholipases A2; Prodrugs; Rats, Sprague-Dawley; Reptilian Proteins; Snake Bites; Time Factors; Viper Venoms | 2016 |
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.
Topics: Acetates; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Indoles; Keto Acids; Lethal Dose 50; Mice; Neurotoxicity Syndromes; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Bites; Snake Venoms; Survival Analysis; Time Factors | 2020 |
Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.
Topics: Acetates; Animals; Crotalid Venoms; Crotoxin; Indoles; Keto Acids; Mice; Myotoxicity | 2021 |